Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker REGN · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 13, 2026 | A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well… NCT06097364 · Follicular Lymphoma (FL) Odronextamab, Rituximab | REGN Regeneron Pharmaceuticals | Phase 3 | Active, not recruiting | 733 | Jul 29, 2029 | Registry ↗ |
| Nov 12, 2026 | Study to Evaluate ALN-CIDEB in Adults With Fibrotic Alcohol-Associated Liver Disease (ALD) NCT07933328 · Alcohol-Associated Liver Disease, ALD ALN-CIDEB, Placebo | REGN Regeneron Pharmaceuticals | Phase 2 | Not yet recruiting | 120 | May 7, 2029 | Registry ↗ |
| Nov 12, 2026 | A Study to Investigate the Safety, Pharmacokinetics (PK), and Efficacy of Garetosmab in Children an… NCT07559513 · Fibrodysplasia Ossificans Progressiva, FOP garetosmab | REGN Regeneron Pharmaceuticals | Phase 3 | Not yet recruiting | 18 | Jul 8, 2030 | Registry ↗ |
| Nov 12, 2026 | A Study Evaluating Mibavademab Treatment of Obesity Due to Leptin (LEP) Gene Mutations in Children,… NCT07220772 · Monogenic Obesity Mibavademab | REGN Regeneron Pharmaceuticals | Phase 3 | Recruiting | 4 | Jun 18, 2027 | Registry ↗ |
| Nov 12, 2026 | A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe a… NCT06299098 · Obesity Trevogrumab-Part A, Trevogrumab-Part B and Part C | REGN Regeneron Pharmaceuticals | Phase 2 | Completed was active, not recruiting | 1,005 | Jun 16, 2026 | Registry ↗ |
| Nov 12, 2026 | A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituxi… NCT06149286 · Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractor… Odronextamab, Lenalidomide | REGN Regeneron Pharmaceuticals | Phase 3 | Recruiting | 580 | Apr 30, 2031 | Registry ↗ |
| Nov 12, 2026 | A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Ritux… NCT06091254 · Follicular Lymphoma (FL) Odronextamab, Rituximab | REGN Regeneron Pharmaceuticals | Phase 3 | Recruiting | 822 | Feb 29, 2028 | Registry ↗ |
| Nov 12, 2026 | A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metaboli… NCT05519475 · Metabolic Dysfunction-Associated SteatoHepatitis (MASH) ALN-HSD, Placebo | REGN Regeneron Pharmaceuticals | Phase 2 | Active, not recruiting was recruiting | 120 | Apr 27, 2028 | Registry ↗ |
| Nov 12, 2026 | Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Sm… NCT03088540 · Carcinoma,Non-Small-Cell Lung, Lung Carcinomas, Non-Small-C… Pemetrexed, Paclitaxel | REGN Regeneron Pharmaceuticals | Phase 3 | Completed | 712 | Apr 18, 2025 | Registry ↗ |
| Nov 10, 2026 | Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis… NCT07830329 · Hidradenitis Suppurativa Olatorepatide, Placebo | REGN Regeneron Pharmaceuticals | Phase 2 | Recruiting was not yet recruiting | 300 | Nov 24, 2028 | Registry ↗ |
| Nov 10, 2026 | Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Ora… NCT07430956 · Atrial Fibrillation (AF) REGN7508, REGN9933 | REGN Regeneron Pharmaceuticals | Phase 3 | Recruiting | 2,628 | Mar 28, 2029 | Registry ↗ |
| Nov 10, 2026 | A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Me… NCT06848088 · Melanoma Fianlimab+cemiplimab | REGN Regeneron Pharmaceuticals | Phase 2 | Active, not recruiting was enrolling by invitation | 28 | Oct 9, 2030 | Registry ↗ |
| Nov 10, 2026 | A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for… NCT05608291 · Melanoma Fianlimab, Cemiplimab | REGN Regeneron Pharmaceuticals | Phase 3 | Active, not recruiting | 1,564 | Jan 15, 2027 | Registry ↗ |
| Nov 9, 2026 | Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatiti… NCT07631637 · Metabolic Dysfunction-Associated Steatohepatitis, MASH ALN-CIDEB, Placebo | REGN Regeneron Pharmaceuticals | Phase 2 | Recruiting | 360 | Jan 29, 2029 | Registry ↗ |
| Nov 9, 2026 | A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Pr… NCT05568459 · Hemophilia B Non-Interventional | REGN Regeneron Pharmaceuticals | — | Active, not recruiting | 11 | Nov 20, 2026 | Registry ↗ |
| Nov 6, 2026 | Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes NCT07685808 · Overweight or Obesity Olatorepatide, Placebo | REGN Regeneron Pharmaceuticals | Phase 2 | Recruiting | 360 | Jan 21, 2028 | Registry ↗ |
| Nov 6, 2026 | First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With… NCT07527923 · Healthy Volunteer, Atopic Dermatitis REGN20423, Placebo | REGN Regeneron Pharmaceuticals | Phase 1 | Recruiting | 160 | Aug 14, 2028 | Registry ↗ |
| Nov 6, 2026 | REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adu… NCT07015905 · Venous Thromboembolism (VTE) REGN7508, Apixaban | REGN Regeneron Pharmaceuticals | Phase 3 | Recruiting | 2,000 | Feb 20, 2027 | Registry ↗ |
| Nov 6, 2026 | Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovari… NCT06787612 · Ovarian Cancer, Fallopian Tube Cancer Ubamatamab, Bevacizumab | REGN Regeneron Pharmaceuticals | Phase 2 | Recruiting | 397 | Jun 30, 2028 | Registry ↗ |
| Nov 6, 2026 | A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advance… NCT06246916 · Melanoma fianlimab, cemiplimab | REGN Regeneron Pharmaceuticals | Phase 3 | Recruiting | 560 | Mar 22, 2027 | Registry ↗ |
| Nov 6, 2026 | A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it… NCT05828511 · Multiple Myeloma Linvoseltamab | REGN Regeneron Pharmaceuticals | Phase 1/2 | Active, not recruiting was recruiting | 148 | Nov 2, 2035 | Registry ↗ |
| Nov 6, 2026 | A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomi… NCT05730036 · Relapsed Refractory Multiple Myeloma (RRMM) Linvoseltamab, Elotuzumab | REGN Regeneron Pharmaceuticals | Phase 3 | Recruiting | 410 | Apr 19, 2033 | Registry ↗ |
| Nov 6, 2026 | A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in… NCT05133531 · Paroxysmal Nocturnal Hemoglobinuria Ravulizumab, Pozelimab | REGN Regeneron Pharmaceuticals | Phase 3 | Completed was active, not recruiting | 202 | Sep 28, 2026 | Registry ↗ |
| Nov 5, 2026 | Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease… NCT07854782 · Metabolic Dysfunction-Associated Steatotic Liver Disease, M… ALN-CIDEB, Placebo | REGN Regeneron Pharmaceuticals | Phase 3 | Recruiting was not yet recruiting | 1,500 | Mar 3, 2029 | Registry ↗ |
| Nov 5, 2026 | A Study to Evaluate the Efficacy and Safety of Fel d 1 Monoclonal Antibodies in Adult and Pediatric… NCT07675811 · Allergic Conjunctivitis REGN-2Cat, Freneslerbart | REGN Regeneron Pharmaceuticals | Phase 3 | Recruiting | 570 | May 31, 2029 | Registry ↗ |
| Nov 5, 2026 | Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation NCT07626411 · Atrial Fibrillation (AF) REGN7508, Apixaban | REGN Regeneron Pharmaceuticals | Phase 3 | Recruiting | 15,364 | Sep 11, 2029 | Registry ↗ |
| Nov 5, 2026 | Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid… NCT07493304 · Venous Thromboembolism (VTE) REGN7508, Apixaban | REGN Regeneron Pharmaceuticals | Phase 3 | Recruiting | 1,600 | Jul 18, 2031 | Registry ↗ |
| Nov 5, 2026 | A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants… NCT07455851 · Relapsed Refractory Multiple Myeloma (RRMM) Linvoseltamab, REGN17372+Linvoseltamab | REGN Regeneron Pharmaceuticals | Phase 1/2 | Recruiting | 150 | Sep 30, 2033 | Registry ↗ |
| Nov 5, 2026 | REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis NCT07410117 · Cancer-Associated Thrombosis (CAT) REGN7508, Placebo | REGN Regeneron Pharmaceuticals | Phase 3 | Recruiting | 1,120 | Jan 23, 2030 | Registry ↗ |
| Nov 5, 2026 | Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral… NCT07318610 · Peripheral Artery Disease (PAD) REGN7508, REGN9933 | REGN Regeneron Pharmaceuticals | Phase 3 | Recruiting | 7,050 | Aug 18, 2029 | Registry ↗ |
| Nov 5, 2026 | REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthropla… NCT07213778 · Symptomatic Venous Thromboembolism (VTE) REGN7508, Acetylsalicylic Acid (ASA) | REGN Regeneron Pharmaceuticals | Phase 3 | Recruiting | 2,000 | May 17, 2027 | Registry ↗ |
| Nov 5, 2026 | Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation NCT07175428 · Atrial Fibrillation (AF) REGN7508, REGN9933 | REGN Regeneron Pharmaceuticals | Phase 2 | Recruiting | 1,200 | Feb 9, 2027 | Registry ↗ |
| Nov 5, 2026 | A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdi… NCT06541704 · Age-related Macular Degeneration (AMD), Geographic Atrophy… Pozelimab, Cemdisiran | REGN Regeneron Pharmaceuticals | Phase 3 | Recruiting | 975 | Jul 31, 2028 | Registry ↗ |
| Nov 5, 2026 | A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-… NCT05744921 · Paroxysmal Nocturnal Hemoglobinuria Pozelimab, Cemdisiran | REGN Regeneron Pharmaceuticals | Phase 3 | Recruiting | 202 | Oct 10, 2028 | Registry ↗ |
| Nov 5, 2026 | A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Trea… NCT05137054 · Multiple Myeloma Linvoseltamab, Daratumumab | REGN Regeneron Pharmaceuticals | Phase 1 | Recruiting | 317 | Mar 25, 2028 | Registry ↗ |
| Nov 4, 2026 | A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma… NCT07393282 · High Risk Smoldering Multiple Myeloma (HR-SMM) Linvoseltamab, Daratumumab | REGN Regeneron Pharmaceuticals | Phase 3 | Recruiting | 270 | Jul 27, 2033 | Registry ↗ |
| Nov 4, 2026 | A Study to Investigate Mibavademab in Adult Women With Functional Hypothalamic Amenorrhea NCT07235917 · Functional Hypothalamic Amenorrhea, FHA Mibavademab, Placebo | REGN Regeneron Pharmaceuticals | Phase 2 | Recruiting | 34 | Jan 28, 2028 | Registry ↗ |
| Nov 4, 2026 | A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy Wi… NCT07222761 · Relapsed and/or Refractory Multiple Myeloma (RRMM) Linvoseltamab, Carfilzomib | REGN Regeneron Pharmaceuticals | Phase 3 | Recruiting | 915 | May 21, 2029 | Registry ↗ |
| Nov 4, 2026 | A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic… NCT06836609 · Metabolic Dysfunction-Associated Steatotic Liver Disease, M… ALN-CIDEB, Placebo | REGN Regeneron Pharmaceuticals | Phase 1/2 | Active, not recruiting was recruiting | 118 | Aug 17, 2027 | Registry ↗ |
| Nov 4, 2026 | A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Agains… NCT06091865 · Diffuse Large B-cell Lymphoma (DLBCL) Odronextamab, Rituximab | REGN Regeneron Pharmaceuticals | Phase 3 | Recruiting | 904 | Mar 30, 2028 | Registry ↗ |
| Nov 4, 2026 | A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination… NCT03972657 · Metastatic Castration-Resistant Prostate Cancer (mCRPC), Cl… REGN5678, Cemiplimab | REGN Regeneron Pharmaceuticals | Phase 1/2 | Recruiting | 345 | Nov 15, 2027 | Registry ↗ |
| Nov 3, 2026 | A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treat… NCT06465329 · Non Small Cell Lung Cancer, NSCLC Cemiplimab, Platinum-based chemotherapy | REGN Regeneron Pharmaceuticals | Phase 2 | Active, not recruiting | 184 | Dec 4, 2029 | Registry ↗ |
| Nov 3, 2026 | Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Yea… NCT02612454 · Atopic Dermatitis Dupilumab | REGN Regeneron Pharmaceuticals | Phase 3 | Completed was active, not recruiting | 880 | Oct 9, 2026 | Registry ↗ |
| Oct 30, 2026 | A Study Comparing Cemiplimab-based Treatments for Adult Participants With Locally Advanced Basal Ce… NCT07808515 · Locally Advanced Basal Cell Carcinoma Cemiplimab, Vidutolimod | REGN Regeneron Pharmaceuticals | Phase 2 | Not yet recruiting | 135 | Nov 13, 2030 | Registry ↗ |
| Oct 30, 2026 | An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients Wit… NCT05363319 · Non-small Cell Lung Cancer Cemiplimab, Platinum-based chemotherapy | REGN Regeneron Pharmaceuticals | — | Active, not recruiting was recruiting | 509 | Oct 3, 2028 | Registry ↗ |
| Oct 28, 2026 | Linvoseltamab Versus Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-Vcd) in Adu… NCT07901725 · Newly Diagnosed Amyloidosis, Amyloidosis Stage I-IIIA Linvoseltamab, Daratumumab | REGN Regeneron Pharmaceuticals | Phase 3 | Not yet recruiting | 382 | Jul 25, 2035 | Registry ↗ |
| Oct 28, 2026 | A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and… NCT05070858 · Generalized Myasthenia Gravis Pozelimab + Cemdisiran, Cemdisiran | REGN Regeneron Pharmaceuticals | Phase 3 | Active, not recruiting | 288 | Jul 8, 2025 | Registry ↗ |
| Oct 27, 2026 | Safety and Tolerability of REGN17235 in Adult Participants With Clonal Cytopenia of Undetermined Si… NCT07753148 · Clonal Cytopenia of Undetermined Significance (CCUS), Low-R… REGN17235 | REGN Regeneron Pharmaceuticals | Phase 1 | Recruiting | 52 | May 5, 2031 | Registry ↗ |
| Oct 27, 2026 | Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Releas… NCT07609940 · Relapsed/Refractory Multiple Myeloma (RRMM) Linvoseltamab, Tocilizumab | REGN Regeneron Pharmaceuticals | Phase 4 | Recruiting | 30 | Oct 11, 2027 | Registry ↗ |
| Oct 27, 2026 | Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease NCT07271186 · Diabetic Kidney Disease (DKD) ALN-ANG3, Evinacumab | REGN Regeneron Pharmaceuticals | Phase 2 | Recruiting | 195 | Oct 13, 2028 | Registry ↗ |
The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 10:30 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances